These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 3104195)
21. Preparation of monoclonal antibodies against Mycobacterium tuberculosis TB10.4 antigen. Chen X; Ou Z; Xie XL; Xu ZZ; Jiao XA Monoclon Antib Immunodiagn Immunother; 2014 Dec; 33(6):444-7. PubMed ID: 25545212 [TBL] [Abstract][Full Text] [Related]
22. Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. III. Polyvalent serum against three mucoid immunotypes potentiates phagocytosis of all (7) mucoid immunotypes. Gościniak G; Grzybek-Hryncewicz K Arch Immunol Ther Exp (Warsz); 1988; 36(2):195-203. PubMed ID: 3149178 [TBL] [Abstract][Full Text] [Related]
23. The isolation of cross-reactive monoclonal antibodies: hybridomas to streptococcal antigens cross-reactive with mammalian basement membrane. Fitzsimons EJ; Weber M; Lange CF Hybridoma; 1987 Feb; 6(1):61-9. PubMed ID: 3679253 [TBL] [Abstract][Full Text] [Related]
24. Surveillance of gram-negative bacteria for Pseudomonas aeruginosa lipoprotein I using a monoclonal antibody. Sciortino CV Hybridoma; 1993 Jun; 12(3):327-32. PubMed ID: 7689535 [TBL] [Abstract][Full Text] [Related]
25. The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium, Pseudomonas aeruginosa. Markham RB; Pier GB; Schreiber JR J Immunol; 1991 Jan; 146(1):316-20. PubMed ID: 1898604 [TBL] [Abstract][Full Text] [Related]
26. Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. I. Induction of homologous immunity by nonmucoid strains of P. aeruginosa. Gościniak G; Grzybek-Hryncewicz K Arch Immunol Ther Exp (Warsz); 1988; 36(2):177-84. PubMed ID: 2467637 [TBL] [Abstract][Full Text] [Related]
28. Generation of monoclonal antibodies against surface antigens of Moraxella bovis. Aleixo JA; Barbosa RC; Gil-Turnes C Hybridoma; 1991 Oct; 10(5):625-31. PubMed ID: 1804773 [TBL] [Abstract][Full Text] [Related]
29. [Effects of human gamma globulin preparations and monoclonal antibody on the whole blood chemiluminescence response]. Tsuji A; Asahara M; Aoki Y; Kitaya S; Ohono A; Goto S; Kaneko H Kansenshogaku Zasshi; 1987 Sep; 61(9):1015-22. PubMed ID: 2450934 [No Abstract] [Full Text] [Related]
30. Anti-idiotype-induced, lipopolysaccharide-specific antibody response to Pseudomonas aeruginosa. Schreiber JR; Patawaran M; Tosi M; Lennon J; Pier GB J Immunol; 1990 Feb; 144(3):1023-9. PubMed ID: 2104908 [TBL] [Abstract][Full Text] [Related]
31. [Characteristics of monoclonal antibodies directed to species specific and group specific antigens of Rickettsia prowazekii]. Drobyshevskaia EI; Nedialkov IuA; Spitsin SV; Makarova VA; Tarasevich IV; Nesterenko VG Tr Inst Im Pastera; 1989; 66():160-5, 175. PubMed ID: 2485302 [TBL] [Abstract][Full Text] [Related]
32. Conjugation of alginate to a synthetic peptide containing T- and B-cell epitopes as an induction for protective immunity against Pseudomonas aeruginosa. Farjaha A; Owlia P; Siadat SD; Mousavi SF; Shafieeardestani M J Biotechnol; 2014 Dec; 192 Pt A():240-7. PubMed ID: 25449544 [TBL] [Abstract][Full Text] [Related]
33. Nonopsonic phagocytosis of Pseudomonas aeruginosa by macrophages and polymorphonuclear leukocytes requires the presence of the bacterial flagellum. Mahenthiralingam E; Speert DP Infect Immun; 1995 Nov; 63(11):4519-23. PubMed ID: 7591095 [TBL] [Abstract][Full Text] [Related]
34. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine. Barclay GR; Yap PL; McClelland DB; Jones RJ; Roe EA; McCann MC; Micklem LR; James K J Med Microbiol; 1986 Feb; 21(1):87-90. PubMed ID: 3081727 [TBL] [Abstract][Full Text] [Related]
35. Heterohybridomas that secrete high levels of pseudomonas-specific therapeutic human monoclonal antibodies: their generation and large scale growth in an automated hollow fiber cell culture system. Gammon MC; Banas MH; Boccumini LE; Sigal NH; Zweerink HJ Cytotechnology; 1990 Jan; 3(1):51-60. PubMed ID: 1367460 [TBL] [Abstract][Full Text] [Related]
37. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. Moriyama K; Wiener-Kronish JP; Sawa T Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258 [TBL] [Abstract][Full Text] [Related]
38. Investigation of a panel of monoclonal antibodies and polyclonal sera against anthrax toxins resulted in identification of an anti-lethal factor antibody with disease-enhancing characteristics. Kulshreshtha P; Tiwari A; Priyanka ; Joon S; Sinha S; Bhatnagar R Mol Immunol; 2015 Dec; 68(2 Pt A):185-93. PubMed ID: 26364143 [TBL] [Abstract][Full Text] [Related]
39. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury. Wang Q; Li H; Zhou J; Zhong M; Zhu D; Feng N; Liu F; Bai C; Song Y Respir Physiol Neurobiol; 2014 Mar; 193():21-8. PubMed ID: 24418353 [TBL] [Abstract][Full Text] [Related]
40. Combination therapy of Pseudomonas aeruginosa pyelonephritis in neutropenic mice with human antilipopolysaccharide monoclonal antibody and cefsulodin. Ishibashi K; Yamaguchi O; Shiraiwa Y; Ogihara M; Shigeta S J Urol; 1996 Jun; 155(6):2094-7. PubMed ID: 8618343 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]